Inactive Ingredient Search for Approved Drug Products

• Share
• Tweet
• Linkedin
• Pin it
• More sharing options
  • Linkedin
  • Pin it
• Email
• Print

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with L

	Quarter	Inactive Ingredient	Route of Administration	Dosage Form	Maximum Potency per unit dose	Maximum Daily Exposure	Status
4114	Q3 2021	LACTOSE MONOHYDRATE	ORAL	TABLET, FILM COATED, EXTENDED RELEASE	260.00 mg		MDE Replacement
4114	Q4 2021	LACTOSE MONOHYDRATE	ORAL	TABLET, FILM COATED, EXTENDED RELEASE		520 mg	MDE Replacement
4240	Q3 2021	LIGHT MINERAL OIL	TOPICAL	CREAM	20.00 %w/w		MDE Replacement
4240	Q4 2021	LIGHT MINERAL OIL	TOPICAL	CREAM		456 mg	MDE Replacement
4270	Q3 2021	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW)	ORAL	TABLET	80.00 mg		MDE Replacement
4270	Q4 2021	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW)	ORAL	TABLET		369.6 mg	MDE Replacement
4272	Q3 2021	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW)	ORAL	TABLET, DELAYED RELEASE	26.30 mg		MDE Replacement
4272	Q4 2021	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW)	ORAL	TABLET, DELAYED RELEASE		84 mg	MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: September 30, 2021
Database Last Updated: October 21, 2021